Advertisement

Topics

Latest Top Pharmaceutical Companies in India NewsRSS

00:04 EST 17th December 2018 | BioPortfolio

Prestige BioPharma Partners with Cipla to Market Key Cancer Biosimilar

NewsThe licensing agreement for the HD20 trastuzumab biosimilar gives Cipla Ltd. exclusive rights to distribute and market the drug in selected emerging markets.

Sanofi's Lantus Insulin Patent Infringement Claims Against Mylan Reportedly Rejected

NewsMylan's NDA for generic versions of Lantus and Lantus SoloSTAR, co-developed with Biocon, is under active review by the FDA.

Prestige BioPharma Partners with Cipla Ltd to Market Key Cancer Biosimilar

    Singapore, December 14, 2018 / B3C newswire / -- Prestige BioPharma (“Prestige”) announced today that it has reached a licensing agreement with

FDA gives Lupin’s generic Tecfidera tentative approval

BioSim Pharmaceuticals to Attend JP Morgan Healthcare Conference in San Francisco

Held annually alongside Biotech Showcase and OneMed Forum, the JP Morgan conference is one of the largest and most informative healthcare symposiums in the industry. BioSim will be meeting throughout the conference to update suppliers and interested parties on state of their research and development program. BioSim’s ACTH Gelatin Depot 80 IU/mL ...

Indivior succeeds in putting Suboxone generic on hold again

Indiviorâs patent litigation with Dr. Reddyâs over Suboxone film continues after the company announced its preliminary injunction will stay in place.

Cipla Ltd CIPLA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryCipla Ltd Cipla is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients APIs. It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, ne...

Indivior prevails in attempt to stall US launch of Dr. Reddy's Suboxone generic https://www.firstwordpharma.com/node/1611017  $INDV

Indivior prevails in attempt to stall US launch of Dr. Reddy's Suboxone generic https://www.firstwordpharma.com/node/1611017  $INDV

Lupin introduces generic Rapaflo

FDA gives Lupin’s generic Eliquis tentative approval

Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market a...

Cadila Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryCadila Pharmaceuticals Ltd Cadila develops, manufactures and distributes pharmaceutical products. The company's products include active pharmaceutical ingredients API and pharmaceutical formulations. It offers products in the form of capsules, tablets, orals, soft and hard gelatin capsules, and liquid solutions. The company's business operations include contract research, contract manufactu...

Way cleared in US for Suboxone and Zytiga generics

The US Court of Appeals is clearing the way for generics competitors to enter the market. The court has lifted an injunction on Dr Reddy’s Suboxone (buprenorphine/naloxone) generic and upheld a decision to invalidate Johnson & Johnson’s (J&J) patent on its blockbuster prostate cancer drug Zytiga (abiraterone).

Glenmark gains FDA approval for MS and pneumonia generics

In November 2018, Indian generics maker Glenmark Pharmaceuticals (Glenmark) announced the approval of generics for the treatment of multiple sclerosis (MS) and pneumonia.

US FDA notes 22 observations at Lupin’s Indian base

Lupin has received 22 observations across three facilities at its Mandideep campus, which the company says are only âprocedural in natureâ.

Lupin Ltd LUPIN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryLupin Ltd Lupin focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients APIs. The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastrointestinal, antiinfectives, nonsteroidal antiinflammatory drugs NSAIDs, antiTB and cephalosporins. It underta...

Patent litigation over Dr. Reddy’s Suboxone generic continues

The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddyâs, which prevented the company from selling its Suboxone generic.

Lupin launches generic nystatin, triamcinolone acetonide cream

Dr. Reddy’s launches generic chlorthalidone tablets

Dr. Reddy's Laboratories Announces the Launch of Chlorthalidone Tablets, USP in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA). ...

Ruling revives launch of Dr. Reddy’s generic Suboxone sublingual film

Lupin gets FDA nod for 2 generics

Dr. Reddy's Laboratories Ltd DRREDDY Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryDr. Reddy's Laboratories Ltd Dr. Reddy's is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, ...

Court opens path for Dr. Reddy's to launch generic Suboxone

A U.S. federal appeals court threw out a preliminary injunction that had blocked the generics maker from launching a copy of Indivior's opioid treatment.

Lupin launches generic Xenazine

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in India market research data and corporate reports here